<div class="modal hidden">
    <button class="close-btn efficacy">
        <i class="fas fa-times"></i>
    </button>
    <h4>A SIGNIFICANTLY LOWER PROPORTION OF
        PATIENTS TREATED WITH TOFACITINIB
        EXPERIENCED A DISEASE FLARE AT WEEK
        44 IN THE DB PHASE COMPARED TO THE
        PLACEBO GROUP</h4>
    <div class="btn-container">
        <button class="modal-btn efficacy">
            TRUE
        </button>
        <button class="modal-btn efficacy">
            FALSE
        </button>
        <div class="result hidden">
            <i class="fas fa-check"></i>
            CORRECT!
        </div>
        <button class="submit efficacy">
            <i class="fas fa-check"></i>
            SUBMIT
        </button>
    </div>
</div>
<section id="efficacy" class="section">
    <nav class="desktop">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy active">
            <i class="fas fa-chart-line"></i>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
        </a>
    </nav>
    <main>
    <div class="top">
        <a href="" ui-sref="LANDING-PAGE"><img src="assets/pfizer-logo.svg" alt="Pfizer Logo"></a>
        <h1>Tofacitinib pcJIA</h1>
    </div>
    <div class="content swiper mySwiper">
        <div class="swiper-wrapper">
            <div class="swiper-slide primary-endpoint-2">
                <a href="" class="audio efficacy"><i class="fas fa-volume-up"></i></a>
                <div class="content-container">
                <h3 class="efficacy-header">PRIMARY ENDPOINT<br> OCCURENCE OF DISEASE FLARE (LOCF<sup>A</sup>) IN DB PHASE (PCJIA/SPJA/ERA)</h3>
                <div class="img-wrapper">
                <img src="assets/efficacy/efficacy-2.svg" class="efficacy-2" alt="Primary Endpoint graph" />
                </div>
                </div>
                <div class="footnotes">
                    <ol>
                        <li>LOCF was used for inputting intermittent missing components and assessments.</li>
                        <li>5 mg BID or equivalent weight-based lower dose in patients &lt;40 kg.</li>
                    </ol>
                    <p>BID, twice daily; DB, double-blind; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; LOCF, last observation carried forward; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.
                    </p>
                    <p>XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Prescribing information. Pfizer, Inc. 2021.</p>
                </div>
            </div>
            <div class="swiper-slide primary-endpoint-1">
                <a href="" class="audio efficacy"><i class="fas fa-volume-up"></i></a>
                <div class="content-container">
                <h3 class="efficacy-header">PRIMARY ENDPOINT<br> OCCURENCE OF DISEASE FLARE AT WEEK 44 in DB PHASE</h3>
                <div class="img-wrapper">
                <img src="assets/efficacy/efficacy-1.svg" class="efficacy-1" alt="Primary Endpoint graph" />
                </div>
                <h4>Double-blind period included responders following an 18-week, open-label run-in period.</h4>
                </div>
                <div class="footnotes">
                    <ol>
                        <li>Flare is defined as a worsening of ≥30% in ≥3 of the 6 variables of the JIA core set, with ≤1 variable improving by ≥30% (Brunner HI et al. J Rheumatol. 2002;29:1058-1064); Week 44 responders represent patients who initalialy responded to 18 weeks of OL tofacitinib treatment.</li>
                        <li>5 mg BID or equivalent weight-based lower dose in patients &lt;40 kg.</li>
                        <li>Normal approximation approach for binomial proportions.</li>
                    </ol>
                    <p>BID, twice daily; DB, double-blind; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; OL, open-label; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.
                    </p>
                    <p>
                        1. Data on file. Pfizer, Inc. 2022. 2. XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Prescribing information. Pfizer, Inc. 2021
                    </p>
                </div>
            </div>
            <div class="swiper-slide secondary-endpoint-1">
                <a href="" class="audio efficacy"><i class="fas fa-volume-up"></i></a>
                <!-- <div class="content-container"> -->
                <h3 class="efficacy-header">SECONDARY ENDPOINT<br> TIME TO DISEASE FLARE<sup>A</sup> IN DB PHASE (PCJIA/JPSA/ERA)</h3>
                <div class="chart-container">
                <div class="img-wrapper">
                <img src="assets/efficacy/efficacy-3.svg" class="efficacy-3" alt="Secondary Endpoint graph" />
                </div>
                <div class="img-wrapper">
                    <h3 class="efficacy-header">TREATMENT</h3>
                    <img src="assets/efficacy/efficacy-4.svg" class="efficacy-4" alt="Secondary Endpoint table">
                </div>
                </div>
                <!-- </div> -->
                <div class="footnotes">
                    <ol>
                        <li>Flare is defined as a worsening of &geq;30% in &geq;3 of the 6 variables of the JIA core set, with &leq;1 variable improving by &geq;30% ( Brunner HI et al. J Rheumatol 2002; 29: 1058 1064);</li>
                        <li>5 mg BID or equivalent weight based lower dose in patients &lt;40 kg.</li>
                    </ol>
                    <p>BID, twice daily; DB, double-blind; ERA, enthesitis-related arthritis; jPsA, juvenile psoriatic arthritis; PBO, placebo; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
                    <p>
                        Data on file. Pfizer Inc., New York, NY
                    </p>
                </div>
            </div>
            <div class="swiper-slide secondary-endpoint-2">
                <a href="" class="audio efficacy"><i class="fas fa-volume-up"></i></a>
                <div class="content-container">
                <h3 class="efficacy-header">SECONDARY ENDPOINT<br>JIA ACR RESPONSE RATES (OBSERVED DATA) IN DB PHASE OVER TIME (PCJIA) IN TOFACITINIB-TREATED PATIENTS</h3>
                <div class="img-wrapper">
                    <img src="assets/efficacy/efficacy-5.svg" class="secondary-endpoint-4" alt="Secondary Endpoint graph" />
                </div>
                <div class="footnotes">
                    <ol>
                        <li>The JIA ACR30/50/70 response criteria are: 3 of 6 JIA core set variables improved &geq;30%, 50%, and 70%, respectively, with &leq;1 out of 6 JIA core set variables worsened by &geq;30%. In patients with systemic JIA, the absence of spiking fever related to systemic JIA is also required.</li>
                        <li>5 mg BID or equivalent weight-based lower dose in patients &lt;40 kg.</li>
                    </ol>
                    <p>
                    ACR, American College of Rheumatology; BID, twice daily; DB, double-blind; ERA, enthesitis-related arthritis; JIA, juvenile idiopathic arthritis; jPsA, juvenile psoriatic arthritis; OL, open-label; pcJIA, polyarticular course juvenile idiopathic arthritis.</p>
                    <p>1. Data on file. Pfizer, Inc. 2022. 2. XELJANZ/XELJANZ XR/XELJANZ Oral Solution. Prescribing information. Pfizer, Inc. 2021.</p>
                </div>
                </div>
            </div>
        </div>
        <div class="swiper-button-next efficacy">
            NEXT
        </div>
        <div class="swiper-button-prev efficacy">PREVIOUS</div>
        <div class="swiper-pagination efficacy"></div>
        </div>
        <button class="review-btn efficacy vis-hidden">
            <i class="fas fa-question"></i>
            <h5>REVIEW</h5>
        </button>
    </main>
</div>
    <nav class="mobile">
        <a href="" ui-sref="MOA" class="moa">
            <i class="fas fa-atom"></i>
            <h5>MOA</h5>
        </a>
        <a href="" ui-sref="CT" class="ct">
            <i class="fas fa-users"></i>
            <h5>Clinical Trials</h5>
        </a>
        <a href="" ui-sref="EFFICACY" class="efficacy active">
            <i class="fas fa-chart-line"></i>
            <h5>Efficacy</h5>
        </a>
        <a href="" ui-sref="SAFETY" class="safety">
            <i class="fas fa-exclamation-triangle"></i>
            <h5>Safety</h5>
        </a>
        <a href="" ui-sref="DOSING" class="dosing">
            <i class="fas fa-prescription"></i>
            <h5>Dosing</h5>
        </a>
    </nav>
</section>
<script src="js/efficacy/swiper-config.js" defer></script>
<script src="js/efficacy/modal.js" defer></script>